142例早期非小细胞肺癌SBRT长期预后观察

doi:10.3760/cma.j.cn113030-20190325-00107

Abstract
Figure/Table
References(25)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To evaluate the clinical efficacy and safety of stereotactic body radiation therapy (SBRT) for stage Ⅰ-Ⅱ non-small cell lung cancer. Methods Retrospective analysis of patients with early stage lung cancer who received SBRT in Zhejiang Cancer Hospital from 2012 to 2018 was conducted. The Kaplan-Meier method was used for survival analysis. The main endpoints of the study were locoregional control (LRC) and cancer specific survival (CSS). Results A total of 142 eligible cases were included,with a median BED10100Gy (100-132Gy). The median age was 75.6 years (47.2-89.0 years),among which 75 patients were aged (greater than or equal to 75 years old). The median follow-up time was 31.0 months,for patients< 75 years old and patients ≥ 75 years old. The 5-year LRC were 84.5% and 95.8% respectively,5-year CSS were 72.4% and 78.6% respectively,for patients< 75 years old and elderly patients. The systemic response was mild during treatment,no grade 4-5 adverse events occurred in all patients. The main acute side effect was radiation pneumonitis (RP) below grade 3. Grade 2 RP appeared in 14 patients (9.9%) after SBRT where grade 3 RP occurred in 2(1.4%). There was no treatment-related mortality in the SBRT group. Conclusions SBRT is a safe and effective treatment for early primary lung cancer with satisfactory rates of LRC and CSS in 5 years and mild complication,which is similar to previous reports.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Dong Baiqiang
	Wang Jin
	Xu Yujin
	Hu Xiao
	Du Xianghui
	Shan Guoping
	Shao Kainan
	Bai Xue
	Chen Ming

Key words： Lung neoplasms/stereotactic body radiotherapy Treatment outcomes

Received: 25 March 2019

Fund:Zhejiang Public Welfare Fund (2017C33092)

Corresponding Authors: Chen Ming,Email:chenming@zjcc.org.cn

Cite this article:

Dong Baiqiang,Wang Jin,Xu Yujin et al. Experience and efficacy of SBRT for lung cancer:an analysis of 142 patients[J]. Chinese Journal of Radiation Oncology, 2020, 29(6): 416-420.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20190325-00107 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I6/416

[1] Iyengar P, Timmerman RD. Stereotactic ablative radiotherapy for non-small cell lung cancer:rationale and outcomes[J]. JNCCN, 2012, 10(12):1514-1520.
[2] Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer[J]. JAMA, 2010, 303(11):1070-1076. DOI:10.1001/jama.2010.261.
[3] Hurkmans CW, Cuijpers JP, Lagerwaard FJ, et al. Recommendations for implementing stereotactic radiotherapy in peripheral stageⅠ a non-small cell lung cancer:report from the Quality Assurance Working Party of the randomised phase Ⅲ ROSEL study[J]. Radiat Oncol, 2009, 4:1. DOI:10.1186/1748-717x-4-1.
[4] Olsen JR, Robinson CG, El Naqa I, et al. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4):e299-303. DOI:10.1016/j.ijrobp.2011.01.038.
[5] Sun B, Brooks ED, Komaki RU, et al. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage Ⅰ non-small cell lung cancer:results of a phase 2 clinical trial[J]. Cancer, 2017, 123(16):3031-3039. DOI:10.1002/cncr.30693.
[6] Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small cell lung cancer:a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015, 16(6):630-637. DOI:10.1016/s1470-2045(15)70168-3.
[7] Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage Ⅰ nonsmall cell lung carcinoma:clinical outcomes in 245 subjects in a Japanese multi-institutional study[J]. Cancer, 2004, 101(7):1623-1631. DOI:10.1002/cncr.20539.
[8] Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage Ⅰ non-small cell lung cancer:updated results of 257 patients in a Japanese multi-institutional study[J]. J Thorac Oncol, 2007, 2(7 Suppl 3):S94-100. DOI:10.1097/JTO.0b013e318074de34.
[9] Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly[J]. Int J Radiat Oncol Biol Phys, 2012, 84(5):1060-1070. DOI:10.1016/j.ijrobp.2012.07.2354.
[10] Zhang B, Zhu F, Ma X, et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer:a systematic review and meta-analysis[J]. Radiother Oncol, 2014, 112(2):250-255. DOI:10.1016/j.radonc.2014.08.031.
[11] Chi A, Liao Z, Nguyen NP, et al. Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small cell lung cancer:clinical implications[J]. Radiother Oncol, 2010, 94(1):1-11. DOI:10.1016/j.radonc.2009.12.008.
[12] Shibamoto Y, Hashizume C, Baba F, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage Ⅰ non-small cell lung cancer:five-year mature results[J]. J Thorac Oncol, 2015, 10(6):960-964. DOI:10.1097/jto.0000000000000525.
[13] Navarro-Martin A, Aso S, Cacicedo J, et al. Phase Ⅱ Trial of SBRT for stage Ⅰ NSCLC:Survival, Local Control, and Lung Function at 36 Months[J]. J Thorac Oncol, 2016, 11(7):1101-1011. DOI:10.1016/j.jtho.2016.03.021.
[14] van den Berg LL, Klinkenberg TJ, Groen HJ, et al. Patterns of recurrence and survival after surgery or stereotactic radiotherapy for early stage NSCLC[J]. J Thorac Oncol, 2015, 10(5):826-831. DOI:10.1097/jto.0000000000000483.
[15] Crabtree TD, Puri V, Robinson C, et al. Analysis of first recurrence and survival in patients with stage Ⅰ non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy[J]. J Thorac Cardiovasc Surg, 2014, 147(4):1183-1192. DOI:10.1016/j.jtcvs.2013.11.057.
[16] Deng XF, Jiang L, Liu QX, et al. Lymph node micro metastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients:a meta-analysis[J]. J Cardiothorac Surg, 2016, 11:28. DOI:10.1186/s13019-016-0427-x.
[17] Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small cell lung cancer:a retrospective analysis[J]. Lancet Oncol, 2012, 13(8):802-809. DOI:10.1016/s1470-2045(12)70242-5.
[18] Fernandez FG, Kozower BD, Crabtree TD, et al. Utility of mediastinoscopy in clinical stage Ⅰ lung cancers at risk for occult mediastinal nodal metastases[J]. J Thorac Cardiovasc Surg, 2015, 149(1):35-41, 42.e1. DOI:10.1016/j.jtcvs.2014.08.075.
[19] Harris JP, Nwachukwu C, Qian Y, et al. Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer[J]. Lung Cancer, 2018, 124:76-85. DOI:10.1016/j.lungcan.2018.07.033.
[20] Palma D, Senan S. Stereotactic radiation therapy:changing treatment paradigms for stage Ⅰnonsmall cell lung cancer[J]. CurrOpin Oncol, 2011, 23(2):133-139. DOI:10.1097/CCO.0b013e328341ee11.
[21] Mattonen SA, Palma DA, Haasbeek CJ, et al. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer[J]. Med Phys, 2014, 41(3):033502. DOI:10.1118/1.4866219.
[22] Levy A, Guckenberger M, Hurkmans C, et al. SBRT dose and Survival in non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2015, 92(4):945-946. DOI:10.1016/j.ijrobp.2015.03.032.
[23] Videtic GM, Chang JY, Chetty IJ, et al. ACR appropriateness Criteria (R) early-stage non-small cell lung cancer[J]. Am J Clin Oncol, 2014, 37(2):201-207. DOI:10.1097/coc.0000000000000013.
[24] Verstegen NE, Lagerwaard FJ, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage Ⅰ NSCLC:comparison with a contemporaneous cohort with pathologically proven disease[J]. RadiotherOoncol, 2011, 101(2):250-254. DOI:10.1016/j.radonc.2011.09.017.
[25] Timmerman RD, Hu C, Michalski JM, et al. Long-term results of stereotactic body radiation therapy in medically inoperable Stage Ⅰ non-small cell lung cancer[J]. JAMA Oncol, 2018, 4(9):1287-1288. DOI:10.1001/jamaoncol.2018.1258.